KALA BIO, Inc. — Director's Dealing 2023

Jan 7, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2023-01-04

Reporting Person: Kharabi Darius (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-04	Common Stock	A	9525	—	Acquired	15439	Direct

Footnotes

F1: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2024, as to 1/3 of the shares underlying the RSUs on January 4, 2025 and as to the final 1/3 of shares underlying the RSUs on January 4, 2026.

F2: Includes 9,525 unvested RSUs and 1,294 shares of the Issuer's common stock issuable to the Reporting Person in connection with the Issuer's acquisition of Combangio, Inc. and which are being held back by the Issuer until February 15, 2023 as partial security for the satisfaction of indemnification obligations and other payment obligations of the former Combangio equityholders.

F3: The number of shares of common stock reported on this Form 4 reflects a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.